Sectra AB Class B (SE:SECT.B)
:SECT.B
Want to see SE:SECT.B full AI Analyst Report?
Top Page
Sectra AB Class B
(SECT.B)
Select Model
Select Model
Rating:79Outperform
Price Target:
kr335.00
▲(33.79% Upside)
Action:Reiterated
Date:06/07/26
The score is driven primarily by strong financial performance (profitable growth, low leverage, strong ROE) and supportive technical momentum (trend strength and positive MACD). These positives are partially offset by a very expensive valuation (high P/E and low yield) and signs of near-overextended momentum (high Stoch/near-high RSI), which increase downside sensitivity.
Positive Factors
Conservative balance sheet with low leverage and strong ROE
Low debt relative to equity and sustained high ROE give Sectra durable financial flexibility. This conservatism supports funding R&D, pursuing long-term public-sector contracts and acquisitions without relying on external financing, lowering solvency risk over the next several years.
Negative Factors
Decelerating revenue growth in the latest year
A notable slowdown to ~3.5% growth reduces the runway for operating leverage and makes sustaining high ROE harder. If structural demand or competitive pressure caused the deceleration, management will need to invest more to reaccelerate revenue, pressuring margins or cash use.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet with low leverage and strong ROE
Low debt relative to equity and sustained high ROE give Sectra durable financial flexibility. This conservatism supports funding R&D, pursuing long-term public-sector contracts and acquisitions without relying on external financing, lowering solvency risk over the next several years.
Read all positive factors
Sectra AB Class B (SECT.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr54.01B
Dividend Yield0.43%
Average Volume (3M)138.54K
Price to Earnings (P/E)94.6
Beta (1Y)0.45
Revenue Growth9.32%
EPS Growth0.07%
CountrySE
Employees1,234
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)2.93
Shares Outstanding182,017,440
10 Day Avg. Volume126,769
30 Day Avg. Volume138,545
Financial Highlights & Ratios
PEG Ratio254.66
Price to Book (P/B)22.99
Price to Sales (P/S)13.88
P/FCF Ratio48.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)3.68
Revenue Forecast (FY)kr3.81B
Sectra AB Class B Business Overview & Revenue Model
Company Description
Sectra AB (publ), a Swedish company established in Linköping in 1957, specializes in providing advanced information technology solutions for both the medical and cybersecurity fields. Its services are predominantly offered across Europe, including...
How the Company Makes Money
Sectra primarily makes money through two main business areas: medical imaging IT and secure communications/cybersecurity. In medical imaging, it generates revenue by licensing and delivering software platforms (e.g., PACS/RIS and enterprise imagin...
Sectra AB Class B Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
92
Very Positive
Cash Flow
84
Very Positive
| Breakdown | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 | Apr 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.54B | 3.24B | 2.96B | 2.35B | 1.95B |
| Gross Profit | 714.42M | 543.41M | 557.55M | 488.91M | 1.71B |
| EBITDA | 733.07M | 795.35M | 615.06M | 538.55M | 477.28M |
| Net Income | 563.78M | 563.37M | 428.39M | 374.96M | 314.79M |
Balance Sheet | |||||
| Total Assets | 4.47B | 3.76B | 3.21B | 2.74B | 2.19B |
| Cash, Cash Equivalents and Short-Term Investments | 1.81B | 1.34B | 804.64M | 945.24M | 808.77M |
| Total Debt | 76.48M | 87.46M | 31.79M | 82.26M | 62.62M |
| Total Liabilities | 2.34B | 1.84B | 1.64B | 1.44B | 1.11B |
| Stockholders Equity | 2.14B | 1.92B | 1.57B | 1.30B | 1.08B |
Cash Flow | |||||
| Free Cash Flow | 1.01B | 812.37M | 75.58M | 347.70M | 542.55M |
| Operating Cash Flow | 1.10B | 922.36M | 326.33M | 440.49M | 616.92M |
| Investing Cash Flow | -207.46M | -113.86M | -130.74M | -212.79M | -68.35M |
| Financing Cash Flow | -428.43M | -251.88M | -222.20M | -219.29M | -198.75M |
Sectra AB Class B Technical Analysis
Neutral
250.40
Price Trends
270.81
Positive
239.90
Positive
262.98
Positive
Market Momentum
6.20
Positive
45.46
Neutral
9.43
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SECT.B, the sentiment is Neutral. The current price of 250.4 is below the 20-day moving average (MA) of 288.72, below the 50-day MA of 270.81, and below the 200-day MA of 262.98, indicating a neutral trend. The MACD of 6.20 indicates Positive momentum. The RSI at 45.46 is Neutral, neither overbought nor oversold. The STOCH value of 9.43 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:SECT.B.
Sectra AB Class B Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | kr54.01B | 94.59 | 27.98% | 0.43% | 9.32% | 0.07% | |
73 Outperform | kr7.96B | 107.81 | 1.20% | ― | -2.39% | -46.09% | |
69 Neutral | kr52.81B | 22.39 | 6.91% | 2.16% | -4.14% | 59.50% | |
67 Neutral | kr3.26B | 24.34 | 17.89% | 1.61% | -2.32% | -11.87% | |
58 Neutral | kr12.33B | -2.46 | 3.34% | 0.80% | -5.68% | -1106.19% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | kr1.18B | -1.20 | -50.36% | ― | -24.97% | -366.73% |
* Healthcare Sector Average
SE:SECT.B
Sectra AB Class B
276.80
-34.98
-11.22%
SE:GETI.B
Getinge
193.90
15.53
8.71%
SE:VITR
Vitrolife AB
91.05
-44.55
-32.86%
SE:BICO
BICO Group AB Class B
16.70
-17.18
-50.71%
SE:CEVI
CellaVision AB
136.80
-41.24
-23.16%
SE:XVIVO
Xvivo Perfusion AB
252.80
-26.60
-9.52%
Sectra AB Class B Corporate Events
Sectra lifts dividend as cloud revenue surge drives record results
Jun 5, 2026
Sectra reported record net sales and profit for fiscal 2025/2026, driven by strong growth in recurring and cloud recurring revenue despite a decline in contracted order bookings after last year’s exceptionally large Canadian deal. The compan...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.